Tobi and the next-generation Tobi Podhaler are the gold-standard inhaled antibiotic treatments for cystic fibrosis patients. Long-term treatment with Tobi and Tobi Podhaler treats chronic Pseudomonas aeruginosa infections that are common in cystic fibrosis patients and also has other respiratory benefits such as improving lung function.
LIST OF FIGURES
10 Figure 1: Tobi/Tobi Podhaler for cystic fibrosis – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of Tobi/Tobi Podhaler for cystic fibrosis
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of Tobi/Tobi Podhaler for cystic fibrosis
14 Figure 4: Tobi/Tobi Podhaler sales for cystic fibrosis across the US and five major EU markets, by country, 2016–25
LIST OF TABLES
6 Table 1: Tobi/Tobi Podhaler drug profile
7 Table 2: Tobi/Tobi Podhaler Phase III data in cystic fibrosis
15 Table 3: Tobi/Tobi Podhaler sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016–25
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.